Skip to content

Psychedelic-assisted therapy: all studies

Page 19 of 294: studies 181 to 190 of 2,936, newest first. Back to the psychedelic-assisted therapy overview

Research

Psychedelic-Assisted Therapy Training in the US: A Landscape Analysis

PsyArXiv July 10, 2025 Roman Palitsky, Caroline Peacock, Jeffrey A. Breau et al. preprint

Skilled interpersonal support and safety monitoring can enhance the therapeutic potential of psychedelic compounds and reduce the potential for harm. In the anticipation of legalized psychedelic care, and the recognition of ongoing psychedelic use across a variety of contexts, numerous training programs have been established to educate psychedelic facilitators in supporting individuals who take...

Clinical Psychedelic Therapy Research Involving Adolescents: Protocol for a Scoping Review of Intervention Studies

Wellcome Open Research July 8, 2025 Khaleel Rajwani, Melanie Almonte, F. Feroz et al. 2 citations

Background Recent years have seen renewed clinical interest in the therapeutic potential of classical psychedelics, such as psilocybin, LSD, DMT, and mescaline. While modern studies have focused on adult populations, adolescents under 18 are routinely excluded due to regulatory, legal, and ethical challenges. Although there exists observational data and historical studies from 1959 to 1974...

"Honoring Beautiful Connections": LGBTQA+ Perspectives on Providing Safe and Inclusive Psychedelic-Assisted Therapy.

Journal of Homosexuality July 8, 2025 Riccardo Miceli Mcmillan, James A Fowler, Tamara C. Erbacher et al. 2 citations

Psychedelic-Assisted Therapy (PAT) is a rapidly growing therapeutic approach that to date has rarely considered the nuanced needs of LGBTQA+ individuals. This study explores what LGBTQA+ individuals consider important for healthcare providers (HCPs) to consider when providing PAT. A global sample of LGBTQA+ individuals aged 18+ who had experience using a classic psychedelic compound at least...

DOI: 10.1080/00918369.2025.2526046 (opens in new tab) Full text (opens in new tab) Lgbtqia+ Psychedelics Acceptability Affirming care +8

Efficient Acyloxymethylation of Psilocin and Other Tryptamines Yielding ACOM Prodrugs for Psychedelic-Assisted Therapy.

Archiv der Pharmazie July 1, 2025 Judith Stirn, Christian D. Klein

Acyloxymethyl (ACOM) derivatives of tryptamines such as the psychedelic drug psilocin and the anti-migraine drug sumatriptan bear potential as prodrugs. Previous synthetic approaches suffer from insufficient chemoselectivity between the desired functionalization of the phenolic (psilocin) or sulfonamide (sumatriptan) groups versus other reactive groups in the parent drugs. We report a novel...

DOI: 10.1002/ardp.70022 (opens in new tab) Full text (opens in new tab) Psilocin Acom prodrug Psychedelic‐assisted therapy Therapeutic outcomes +6

Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression

Journal of Psychopharmacology July 1, 2025 Ryan M Brudner, Erica Kaczmarek, Marc G Blainey et al. 3 citations

Background: Psilocybin-assisted psychotherapy (PAP) is a promising treatment for various psychiatric disorders. However, the exact biological and psychological mechanisms of action of PAP remain to be determined. Examining predictors of PAP outcomes may help identify necessary processes for positive treatment outcomes. Mystical experiences are considered a key aspect of the subjective effects...

Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment

Medical Science Monitor June 30, 2025 Andrzej Silczuk, Robert Madejek, Tytus Koweszko et al. 4 citations

Psychedelics, derived from the Greek words "psyche" (soul) and "deloun" (revealing), are substances historically and currently considered "soul-revealing". Also termed hallucinogens due to their impact on sensory perception, they are further categorized into hallucinogens, such as lysergic acid diethylamide (LSD), psilocybin, and mescaline; entactogens or empathogens, such as...

DOI: 10.12659/msm.948302 (opens in new tab) Mental health Medline Psychotherapist Intensive care medicine

Exploring the integration of psychedelic-assisted therapy and digital mental health interventions in trauma recovery for underserved adults with high-functioning autism

Magna Scientia Advanced Research and Reviews June 28, 2025 Paul Okugo Imoh, Aderonke Ajiboye, Tahir Kolawole Balogun et al. 5 citations

Trauma-related disorders and substance use are disproportionately underdiagnosed and undertreated in individuals with High-Functioning Autism (Level 1 Autism Spectrum Disorder), particularly those in underserved or marginalized communities. Emerging evidence suggests that psychedelic-assisted therapies—including psilocybin, MDMA, and ketamine—offer promising outcomes in the treatment of...

DOI: 10.30574/msarr.2025.14.1.0079 (opens in new tab) Full text (opens in new tab) Psychological intervention Mental health Autism Clinical psychology +1

The Use, Role, and Function of Music During Psychedelic-Assisted Therapy (PAT) with Ayahuasca: A Scoping Review Protocol

Psychoactives June 25, 2025 Guillermo Escobar-Cornejo, Fernando P. Cárdenas, Diego Torres et al.

Objective: To provide a state of the art on the use, role, and function of music during psychedelic-assisted therapy (PAT) with ayahuasca. Introduction: Ayahuasca is a medicinal brew with psychoactive qualities used by indigenous communities throughout the Amazon region, and music is deemed crucial during ayahuasca experiences. In PAT, music forms part of the set and setting, but it lacks...

DOI: 10.3390/psychoactives4020009 (opens in new tab) Full text (opens in new tab) Psychedelic therapy DMT Dimethyltryptamine Psychedelic-assisted therapy pat Yagé +12